Search Results

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

If your team is designing covalent or tight-binding candidates, these principles reduce surprises and Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models Kenakin… sorely needed in the field." — DrGPCR University Attendee 🚀 Join now — and learn to design

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical

GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery committed to leveraging his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical GPCR About Cam Sinh Lu Cam Sinh Lu is a PhD student at Monash Institute of Pharmaceutical Sciences, Monash

These webinars are designed for scientists who want deep, data-driven discussion rather than surface-level chemists working on receptor targets • Structural biologists • Translational scientists • Biotech and pharmaceutical and graduate researchers entering drug discovery If you work directly with receptor systems, ligand design The content is highly relevant for biotech and pharmaceutical scientists. These programs are designed for scientists seeking advanced, mechanism-focused training in GPCR biology